Kidney Disease

221

Pipeline Programs↗

42

Active Trials↗

85

Companies Involved↗

Kidney Disease is a highly competitive landscape with 221 programs across 85 companies. The most active players are Guangdong Raynovent Biotech Co., Ltd, Idorsia Pharmaceuticals Ltd., Inozyme Pharma. 80 therapies are approved with 38 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

82/100

Pipeline Velocity

47/100

Mech. Concentration

6/100

Completion Rate

78/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Guangdong Raynovent Biotech Co., Ltd

2 programs

Idorsia Pharmaceuticals Ltd.

2 programs

Inozyme Pharma

1 program

Grit Biotechnology

1 program

Syndax Pharmaceuticals

1 program

Risen (Suzhou) Pharma Tech Co., Ltd.

1 program

Analysis

Modality Breakdown

90%

Small molecule

210 of 234 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 234 classified programs, each share of the total. Modality classified for 99% of 246 pipeline programs.

Analysis

Trial Status

139

clinical trials

Completed63 · 45%

Recruiting23 · 17%

Unknown status16 · 12%

Not yet recruiting15 · 11%

Terminated14 · 10%

Withdrawn4 · 3%

Other4 · 3%

Clinical Trials

Trial Activity

139 trials

Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease

Recruiting·—·Phase 2·NCT05638880·60 enrolled

Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT05705414·28 enrolled

Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

Recruiting·TThe University of Queensland·N/A·NCT03573089·3,600 enrolled

Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)

Recruiting·SShinshu University·Phase 2·NCT05469659·120 enrolled

NAD Augmentation in Diabetes Kidney Disease

Recruiting·—·Phase 2·NCT05759468·140 enrolled

A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT07348237·24 enrolled

An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease

Recruiting·—·Phase 1·NCT07241468·36 enrolled

Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease

Recruiting·RRenJi Hospital·N/A·NCT06344247·48 enrolled

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

Recruiting·MMaze Therapeutics·Phase 2·NCT06830629·56 enrolled

AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease

Recruiting·—·Phase 4·NCT07182422·100 enrolled

CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease

Recruiting·VVanderbilt University Medical Center·Phase 3·NCT05422534·156 enrolled

Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease

Recruiting·—·Phase 2·NCT06969807·120 enrolled

Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities

Recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 2·NCT06794996·45 enrolled

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

Recruiting·GGrit Biotechnology·Phase 1·NCT07389499·30 enrolled

Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease

Recruiting·—·Phase 2·NCT05237388·75 enrolled

Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)